An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 20 Jan 2017 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
- 06 Aug 2015 Planned End Date changed from 1 Dec 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.
- 06 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.